{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:24:27Z","timestamp":1787761467438,"version":"build-2784847793"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017788","name":"ECOG-ACRIN Cancer Research Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017788","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["U10CA180820"],"award-info":[{"award-number":["U10CA180820"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["U10CA180794"],"award-info":[{"award-number":["U10CA180794"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["UG1CA233247"],"award-info":[{"award-number":["UG1CA233247"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["UG1CA233302"],"award-info":[{"award-number":["UG1CA233302"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["UG1CA233270"],"award-info":[{"award-number":["UG1CA233270"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>High-grade chemotherapy-induced peripheral neuropathy (CIPN) represents a dreaded toxicity of cancer treatments. In some cases, it may limit activities of daily living and become permanent. Because many prior studies of CIPN were conducted in breast cancer populations, less is known about CIPN in men. We therefore determined the incidence and correlates of high-grade CIPN in a large cohort of patients with lung cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We collected data from the ECOG-ACRIN E1594 (comparison of 4 chemotherapy regimens: cisplatin-paclitaxel, cisplatin-gemcitabine, cisplatin-docetaxel, carboplatin-paclitaxel) and E4599 (carboplatin-paclitaxel\u2005\u00b1\u2005concurrent and maintenance bevacizumab) clinical trials. We identified cases with grade \u22653 CIPN. Multivariable logistic regression modeling was performed to estimate adjusted odds ratios according to patient characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 1,998 patients included in the study, 167 (8%) developed grade \u22653 CIPN. Grade \u22653 CIPN was associated with higher body mass index (BMI) (P\u2005=\u2005.01), sex (7% for men vs 10% for women; P\u2005=\u2005.005), age (11% for \u226565 years vs 7% for &amp;lt;65 years; P\u2005&amp;lt;\u2005.001), chemotherapy regimen (P\u2005=\u2005.01), and greater number treatment cycles (P\u2005&amp;lt;\u2005.001). In a multivariate model, regimens featuring higher doses of paclitaxel or cisplatin, greater number of chemotherapy cycles, female sex, greater age, and higher BMI remained independently associated with grade \u22653 CIPN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>High-grade CIPN is associated with chemotherapy type and exposure, female sex, greater age, and elevated BMI. Given the ongoing use of cytotoxic agents in established and new (eg, antibody-drug conjugates) treatment regimens, these findings have implications for patient monitoring and treatment selection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf036","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T15:22:03Z","timestamp":1739460123000},"source":"Crossref","is-referenced-by-count":8,"title":["Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancer"],"prefix":"10.1093","volume":"30","author":[{"given":"Mitchell S","family":"von Itzstein","sequence":"first","affiliation":[{"name":"Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center , Dallas, TX ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawsan","family":"Rashdan","sequence":"additional","affiliation":[{"name":"Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center , Dallas, TX ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne E","family":"Dahlberg","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7812-6741","authenticated-orcid":false,"given":"David E","family":"Gerber","sequence":"additional","affiliation":[{"name":"Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center , Dallas, TX ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan B","family":"Sandler","sequence":"additional","affiliation":[{"name":"Oregon Health Sciences University , Portland, OR ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan H","family":"Schiller","sequence":"additional","affiliation":[{"name":"Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center , Dallas, TX ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H","family":"Johnson","sequence":"additional","affiliation":[{"name":"Vanderbilt University , Nashville, TN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Wang","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoxin","family":"Sun","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh S","family":"Ramalingam","sequence":"additional","affiliation":[{"name":"Winship Cancer Center, Emory University , Atlanta, GA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"2025032905350648500_CIT0001","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3389\/fphar.2015.00234","article-title":"Chemotherapy-induced peripheral neurotoxicity and complementary and alternative medicines: progress and perspective","volume":"6","author":"Cheng","year":"2015","journal-title":"Front Pharmacol."},{"key":"2025032905350648500_CIT0002","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"2025032905350648500_CIT0003","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3390\/ijms20061451","article-title":"Mechanisms of chemotherapy-induced peripheral neuropathy","volume":"20","author":"Zajaczkowska","year":"2019","journal-title":"Int J Mol Sci."},{"key":"2025032905350648500_CIT0004","doi-asserted-by":"publisher","first-page":"329","DOI":"10.5306\/wjco.v8.i4.329","article-title":"Platinum-induced neurotoxicity: a review of possible mechanisms","volume":"8","author":"Kanat","year":"2017","journal-title":"World J Clin Oncol"},{"key":"2025032905350648500_CIT0005","doi-asserted-by":"publisher","first-page":"102831","DOI":"10.1016\/j.critrevonc.2019.102831","article-title":"Prevention of chemotherapy-induced peripheral neuropathy: a review of recent findings","volume":"145","author":"Ibrahim","year":"2020","journal-title":"Crit Rev Oncol Hematol."},{"key":"2025032905350648500_CIT0006","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"2025032905350648500_CIT0007","doi-asserted-by":"crossref","first-page":"131-140","DOI":"10.1093\/jnci\/djx140","article-title":"Chemotherapy-associated peripheral neuropathy in patients with early-stage breast cancer: a systematic review","volume":"110","author":"Rivera","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"2025032905350648500_CIT0008","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10549-016-3939-0","article-title":"Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk","volume":"159","author":"Bao","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"2025032905350648500_CIT0009","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1200\/JCO.2015.66.2346","article-title":"Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group Clinical Trials","volume":"34","author":"Hershman","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025032905350648500_CIT0010","doi-asserted-by":"publisher","first-page":"e01312","DOI":"10.1002\/brb3.1312","article-title":"Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy","volume":"9","author":"Molassiotis","year":"2019","journal-title":"Brain Behav"},{"key":"2025032905350648500_CIT0011","doi-asserted-by":"publisher","first-page":"e2036695","DOI":"10.1001\/jamanetworkopen.2020.36695","article-title":"Hemoglobin, body mass index, and age as risk factors for paclitaxel- and oxaliplatin-induced peripheral neuropathy","volume":"4","author":"Mizrahi","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025032905350648500_CIT0012","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.jpain.2009.04.006","article-title":"Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel","volume":"10","author":"Reyes-Gibby","year":"2009","journal-title":"J Pain"},{"key":"2025032905350648500_CIT0013","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"2025032905350648500_CIT0014","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"2025032905350648500_CIT0015","doi-asserted-by":"publisher","first-page":"e0168707","DOI":"10.1371\/journal.pone.0168707","article-title":"Bevacizumab exacerbates paclitaxel-induced neuropathy: a retrospective cohort study","volume":"11","author":"Matsuoka","year":"2016","journal-title":"PLoS One"},{"key":"2025032905350648500_CIT0016","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3892\/br.2017.851","article-title":"Chemotherapy-induced peripheral neuropathy","volume":"6","author":"Zhang","year":"2017","journal-title":"Biomed Rep"},{"key":"2025032905350648500_CIT0017","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40487-021-00168-y","article-title":"Chemotherapy-induced peripheral neuropathy: Epidemiology, pathomechanisms and treatment","volume":"9","author":"Burgess","year":"2021","journal-title":"Oncol Ther"},{"key":"2025032905350648500_CIT0018","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1111\/jns.12333","article-title":"Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity","volume":"24","author":"Park","year":"2019","journal-title":"J Peripher Nerv Syst"},{"key":"2025032905350648500_CIT0019","doi-asserted-by":"publisher","first-page":"e435","DOI":"10.1002\/onco.13527","article-title":"Expanding beyond maximum grade: chemotherapy toxicity over time by age and performance status in advanced non-small cell lung cancer in CALGB 9730 (Alliance A151729)","volume":"26","author":"Wong","year":"2021","journal-title":"Oncologist"},{"key":"2025032905350648500_CIT0020","doi-asserted-by":"publisher","first-page":"100152","DOI":"10.1016\/j.crphar.2022.100152","article-title":"Sex differences in drug effects and\/or toxicity in oncology","volume":"4","author":"Rakshith","year":"2023","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"2025032905350648500_CIT0021","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1200\/JCO.21.02377","article-title":"Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials","volume":"40","author":"Unger","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025032905350648500_CIT0022","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/978-3-319-70178-3_2","article-title":"Sex differences in body composition","volume":"1043","author":"Bredella","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"2025032905350648500_CIT0023","doi-asserted-by":"publisher","first-page":"E46","DOI":"10.5888\/pcd16.180579","article-title":"Racial and ethnic disparities in adult obesity in the United States: CDC\u2019s tracking to inform state and local action","volume":"16","author":"Petersen","year":"2019","journal-title":"Prev Chronic Dis"},{"key":"2025032905350648500_CIT0024","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1200\/JOP.2012.000606","article-title":"Weight-based chemotherapy dosing in obese patients with cancer: back to the future","volume":"8","author":"Lyman","year":"2012","journal-title":"J Oncol Pract"},{"key":"2025032905350648500_CIT0025","doi-asserted-by":"publisher","first-page":"100153","DOI":"10.1016\/j.esmoop.2021.100153","article-title":"Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)\/Associazione Medici Diabetologi (AMD)\/Societa Italiana Endocrinologia (SIE)\/Societa Italiana Farmacologia (SIF) multidisciplinary consensus position paper","volume":"6","author":"Silvestris","year":"2021","journal-title":"ESMO Open"},{"key":"2025032905350648500_CIT0026","doi-asserted-by":"publisher","first-page":"e002349","DOI":"10.1136\/jitc-2021-002349","article-title":"Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors","volume":"9","author":"Ahmed","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"2025032905350648500_CIT0027","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1001\/jamaoncol.2018.5327","article-title":"Association of body fat and risk of breast cancer in postmenopausal women with normal body mass index: a secondary analysis of a randomized clinical trial and observational study","volume":"5","author":"Iyengar","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025032905350648500_CIT0028","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1093\/annonc\/mdx810","article-title":"Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy","volume":"29","author":"Baracos","year":"2018","journal-title":"Ann Oncol"},{"key":"2025032905350648500_CIT0029","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.1016\/j.clnu.2021.08.023","article-title":"Low skeletal muscle mass is a predictor of treatment related toxicity in oncologic patients. A meta-analysis","volume":"40","author":"Surov","year":"2021","journal-title":"Clin Nutr"},{"key":"2025032905350648500_CIT0030","doi-asserted-by":"publisher","first-page":"21501319211068632","DOI":"10.1177\/21501319211068632","article-title":"Incidence of obesity at 1 and 3 years among community dwelling adults: a population-based study","volume":"13","author":"DeJesus","year":"2022","journal-title":"J Prim Care Commun Health"},{"key":"2025032905350648500_CIT0031","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1007\/s00520-019-04695-3","article-title":"Age-related differences in patient-reported and objective measures of chemotherapy-induced peripheral neuropathy among cancer survivors","volume":"27","author":"Wong","year":"2019","journal-title":"Support Care Cancer"},{"key":"2025032905350648500_CIT0032","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ygyno.2018.12.002","article-title":"A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer","volume":"152","author":"Bulls","year":"2019","journal-title":"Gynecol Oncol"},{"key":"2025032905350648500_CIT0033","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1007\/s00520-013-1766-y","article-title":"Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study","volume":"21","author":"Gewandter","year":"2013","journal-title":"Support Care Cancer"},{"key":"2025032905350648500_CIT0034","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1200\/JCO.2016.71.3552","article-title":"Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy","volume":"35","author":"Winters-Stone","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025032905350648500_CIT0035","doi-asserted-by":"publisher","first-page":"913848","DOI":"10.1155\/2012\/913848","article-title":"Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer","volume":"2012","author":"Pike","year":"2012","journal-title":"Chemother Res Pract"},{"key":"2025032905350648500_CIT0036","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3109\/02841868909111182","article-title":"A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group","volume":"28","author":"Adams","year":"1989","journal-title":"Acta Oncol"},{"key":"2025032905350648500_CIT0037","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.lungcan.2019.07.010","article-title":"Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: a meta-analysis","volume":"135","author":"Griesinger","year":"2019","journal-title":"Lung Cancer"},{"key":"2025032905350648500_CIT0038","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/cncr.23583","article-title":"Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer","volume":"113","author":"Ramalingam","year":"2008","journal-title":"Cancer"},{"key":"2025032905350648500_CIT0039","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1200\/JCO.21.01293","article-title":"Weekly cisplatin plus radiation for postoperative head and neck cancer (JCOG1008): a multicenter, noninferiority, phase II\/III randomized controlled trial","volume":"40","author":"Kiyota","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025032905350648500_CIT0040","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","article-title":"Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial","volume":"30","author":"Socinski","year":"2012","journal-title":"J Clin Oncol"},{"key":"2025032905350648500_CIT0041","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/1078155208098584","article-title":"Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer","volume":"15","author":"Dranitsaris","year":"2009","journal-title":"J Oncol Pharm Pract"},{"key":"2025032905350648500_CIT0042","doi-asserted-by":"publisher","first-page":"7461","DOI":"10.1007\/s00520-021-06321-7","article-title":"Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis","volume":"29","author":"Gu","year":"2021","journal-title":"Support Care Cancer"},{"key":"2025032905350648500_CIT0043","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ejca.2009.12.008","article-title":"Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools","volume":"46","author":"Cavaletti","year":"2010","journal-title":"Eur J Cancer"},{"key":"2025032905350648500_CIT0044","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s00520-009-0613-7","article-title":"Feasibility and validity of the patient neurotoxicity questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02","volume":"17","author":"Shimozuma","year":"2009","journal-title":"Support Care Cancer"},{"key":"2025032905350648500_CIT0045","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1007\/s00520-014-2255-7","article-title":"Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review","volume":"22","author":"Mols","year":"2014","journal-title":"Support Care Cancer"},{"key":"2025032905350648500_CIT0046","doi-asserted-by":"publisher","first-page":"e000537","DOI":"10.1136\/esmoopen-2019-000537","article-title":"Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX","volume":"4","author":"Fernandes","year":"2019","journal-title":"ESMO Open"},{"key":"2025032905350648500_CIT0047","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1080\/13696998.2016.1269015","article-title":"Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer","volume":"20","author":"Gharaibeh","year":"2017","journal-title":"J Med Econ"},{"key":"2025032905350648500_CIT0048","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the Phase III KEYNOTE-407 Study","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025032905350648500_CIT0049","doi-asserted-by":"publisher","first-page":"134378","DOI":"10.1016\/j.neulet.2019.134378","article-title":"Metformin reduces c-Fos and ATF3 expression in the dorsal root ganglia and protects against oxaliplatin-induced peripheral sensory neuropathy in mice","volume":"709","author":"Pereira","year":"2019","journal-title":"Neurosci Lett"},{"key":"2025032905350648500_CIT0050","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3389\/fnins.2019.00653","article-title":"Minocycline prevents the development of mechanical allodynia in mouse models of vincristine-induced peripheral neuropathy","volume":"13","author":"Starobova","year":"2019","journal-title":"Front Neurosci"},{"key":"2025032905350648500_CIT0051","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO Guideline Update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyaf036\/62785518\/oyaf036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyaf036\/62785518\/oyaf036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T23:46:45Z","timestamp":1743378405000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf036\/8097980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf036","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,3]]},"article-number":"oyaf036"}}